Shares of Kenvue Inc. (NYSE:KVUE – Get Free Report) have earned a consensus rating of “Hold” from the sixteen analysts that are covering the company, Marketbeat reports. Twelve investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $19.3333.
Several brokerages have recently issued reports on KVUE. Citigroup reduced their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. UBS Group cut their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Barclays reduced their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th.
Check Out Our Latest Stock Report on KVUE
Kenvue Price Performance
Kenvue (NYSE:KVUE – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the prior year, the firm earned $0.24 EPS. Kenvue’s quarterly revenue was up 4.5% on a year-over-year basis. On average, sell-side analysts expect that Kenvue will post 1.16 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.2%. Kenvue’s dividend payout ratio (DPR) is 97.65%.
Insider Transactions at Kenvue
In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.59% of the company’s stock.
Institutional Investors Weigh In On Kenvue
Several hedge funds have recently made changes to their positions in the business. Montag A & Associates Inc. lifted its position in Kenvue by 6.3% during the first quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock worth $175,000 after buying an additional 600 shares during the period. Cornerstone Wealth Group LLC boosted its stake in Kenvue by 5.9% in the 1st quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after buying an additional 606 shares during the last quarter. Physician Wealth Advisors Inc. grew its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares during the period. Mill Creek Capital Advisors LLC increased its stake in shares of Kenvue by 0.6% during the 4th quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock valued at $2,143,000 after acquiring an additional 701 shares during the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management increased its stake in shares of Kenvue by 0.3% during the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock valued at $4,048,000 after acquiring an additional 712 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Stories
- Five stocks we like better than Kenvue
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
-CHEEMS.png){kind=small}
